|

Purinostat Mesylate for Injection Clinical Trials

1 actively recruiting trial

Pipeline

Phase 3: 1

Top Sponsors

  • Chengdu Zenitar Biomedical Technology Co., Ltd1

Indications

  • Recurrent and Refractory Diffuse Large B-cell Lymphoma1
  • Cancer1

Other1 trial

A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.